Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KALA PHARMACEUTICALS, INC.

(KALA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/12/2021 10/13/2021 10/14/2021 10/15/2021 10/18/2021 Date
2.3(c) 2.41(c) 2.38(c) 2.21(c) 1.85 Last
1 616 891 733 731 745 104 2 007 956 5 054 089 Volume
-0.43% +4.78% -1.24% -7.14% -16.29% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 19,9 M - -
Net income 2021 -116 M - -
Net cash position 2021 72,9 M - -
P/E ratio 2021 -1,23x
Yield 2021 -
Sales 2022 65,5 M - -
Net income 2022 -80,9 M - -
Net cash position 2022 29,8 M - -
P/E ratio 2022 -1,92x
Yield 2022 -
Capitalization 120 M 120 M -
EV / Sales 2021 2,37x
EV / Sales 2022 1,38x
Nbr of Employees 188
Free-Float 99,7%
More Financials
Company
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for diseases of the eye. The Company's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, is a short-term... 
Sector
Pharmaceuticals
Calendar
11/11Earnings Release
More about the company
Ratings of Kala Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about KALA PHARMACEUTICALS, INC.
08:07aKALA PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08:01aKALA PHARMACEUTICALS : Announces Appointment of C. Daniel Myers to Board of Directors
AQ
09/22KALA PHARMACEUTICALS : Reports Inducement Grant Under NASDAQ Listing Rule 5635(4)
AQ
09/21KALA PHARMACEUTICALS : Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
AQ
09/07Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021
GL
08/19KALA PHARMACEUTICALS : Reports Inducement Grant Under NASDAQ Listing Rule 5635(4)
AQ
08/18KALA PHARMACEUTICALS : Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
AQ
08/06KALA PHARMACEUTICALS : Oppenheimer Adjusts Kala Pharmaceuticals PT to $15 From $22, Mainta..
MT
08/06KALA PHARMACEUTICALS : HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $11 Fro..
MT
08/06KALA PHARMACEUTICALS : JPMorgan Downgrades Kala Pharmaceuticals to Neutral From Overweight
MT
08/06KALA PHARMACEUTICALS : Wedbush Adjusts Kala Pharmaceuticals' Price Target to $43 From $49,..
MT
08/05KALA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/05KALA PHARMACEUTICALS : Q2 Results Miss Expectations -- Shares Fall
MT
08/05KALA PHARMA : Q2 Earnings Snapshot
AQ
08/05KALA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Stat..
AQ
More news
News in other languages on KALA PHARMACEUTICALS, INC.

- No features available -

More news
Analyst Recommendations on KALA PHARMACEUTICALS, INC.
More recommendations
Chart KALA PHARMACEUTICALS, INC.
Duration : Period :
Kala Pharmaceuticals, Inc. Technical Analysis Chart | KALA | US4831191030 | MarketScreener
Technical analysis trends KALA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 2,21 $
Average target price 14,79 $
Spread / Average Target 569%
EPS Revisions
Managers and Directors
Mark T. Iwicki Chairman, President & Chief Executive Officer
Mary E. Reumuth Chief Financial Officer, Controller & Treasurer
Romulus Kim Brazzell Chief Medical Officer
Hongming Chen Chief Scientific Officer
Steven Zhang Senior Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
KALA PHARMACEUTICALS, INC.-67.40%144
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657